CClinicalTrials.gg
Not yet recruitingNCT07172763SiliconepadsUpdated Sep 22, 2025

The Pressure Relieving Capacity of Siliconepads Compared to Felted Foam to Relieve Caput Metatarsal 2 in a Population With Diabetes

An observational study in Diabete Mellitus and Peripheral Neuropathy, sponsored by University Hospital, Ghent. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by University Hospital, Ghent · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 90 Years
Sex
All
01

Study summary

To evaluate the clinical effectiveness of siliconepads and if they could be an alternative to felted foam used in offloading high risk pressure areas in the plantar forefoot region using plantar pressure measurements.

Also user experience will be evaluated which is an important criterion in the use of this new type of offloading. Comfort, convenience and functionality of both felted foam and siliconepads will be tested to evaluate if siliconepads are more appropriate then felted foam.

Read the detailed description

People with diabetes mellitus (DM) experience increased pressure under the plantar surface of the foot because of morphological, muscular and sensory abnormalities.

One third of these people have deformed feet, usually due to diabetic neuropathy, which causes localized increases in plantar pressure, particularly on the plantar side of the forefoot, where the risk of foot ulcers is high.

Custom-made therapeutic shoes and arch supports are recommended and are part of standard care for patients with foot deformities and a history of ulceration. The pressure under a human foot can be measured using a technique called Pedobarography or plantar pressure measurement, which uses insole- or platform-based pressure and force systems.

Pedobarographic measurements quantify the vertical load experienced by the foot when walking barefoot or with footwear by measuring the pressure on the plantar side. This makes it possible to identify any functional abnormalities in the structure and function of the dynamic foot. Wearing shoes with or without arch supports was reported to reduce peak pressure by 17 to 52% compared to walking barefoot. Furthermore, proof-of-principle studies have shown that reducing peak pressure on the plantar surface to less than 200 kPa (or by at least 25%) halves the risk of ulcer recurrence in people with diabetes over an 18-month period.

Felted foam therapy is, in addition to insoles and shoes, a complementary conservative treatment that facilitates this pressure relief. Felt consists of compressed wool in various thicknesses that distributes the increased pressure over a larger surface area, thereby reducing the peak pressure at a specific point. The location of the peak pressure is then relieved by the felt with a recess at this zone, whereby the pressure is distributed over the surface.

Felted foam, which has been the 3rd offloading method when it comes to local pressure relief after removable and non-removable knee-high devices, has many advantages but also its limitations. The material needs to be replaced weekly but in reality is often replaced every two days because the effect of the felt is limited in time. The thickness of the original felt decreases with wear and the material must not get wet.

Siliconepads, specifically designed for this study (Remedicare, Netherlands), with a CE certificate, could be more resistant than felt and a game changer in the offloading around the ulcer. These siliconepads are now used in treatment of skin tears and adapted for this study so this can be used and applied similarly to felted foam.

02

Conditions studied

  • Diabete Mellitus
  • Peripheral Neuropathy

Keywords

  • Diabetes
  • Sensory peripheral neuropathy
  • Siliconepads
  • Felted foam
  • Plantar pressure measurement
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 80 is below the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University Hospital, Ghent is the lead sponsor of 665 studies on the registry; 156 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diabetic patients with peripheral neuropathy

Inclusion criteria

  • Diabetes, Peripheral neuropathy, able to walk 5 minutes, able to sign informed consent

Exclusion criteria

Exclusion Criteria:

  • No diabetes, No neuropathy, not able to walk without walking aid, not able to sign informed consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
1 Week
Patient registry
Yes

Interventions

  • DeviceSiliconepad

    Plantar pressure measurement

  • DeviceFelted foam

    Plantar pressure measurement

06

What researchers measure

Primary outcomes

  1. Plantar pressure reduction

    Achieve a plantar pressure decrease of 25%, leading to less than 200kpa under the 2nd caput metatarsal region after wearing siliconepads in comparison to barefoot plantar pressure measurement at baseline and after 48 hours. Achieve a plantar pressure decrease of 25% or less then 200kpa in the 2nd caput metatarsal region after wearing felted foam in comparison to barefoot plantar pressure measurement at baseline and after 48 hours.

    Time frame: 48 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07172763
Lead sponsor
University Hospital, Ghent
Responsible party
DienstThoracaleEnVasculaireHeelkunde (Prof. Dr. Caren Randon, University Hospital, Ghent) — Principal investigator
First posted
Sep 15, 2025
Start date
Oct 8, 2025 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Sep 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion